You may also qualify for Phase 1 Program trials. If you made any changes in Pure these will be visible here soon. boundtree continuing education; can you be charged under ucmj after discharge Dr. Drukers vision for the field of translational oncology is similar to our vision of how to move discoveries from laboratories towardthe clinic. What are the latest results? Dr. Kummar loves to spend time with her family, read, and go for long walks. Division head of medical oncology Shivaani Kummar, M.D., FACP Accepting new patients Division head of radiation medicine Arthur Y. Administrative Coordinator, Margaret Rogers Cancer and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Blood Diseases, Cancer and Blood Disorders, Hematology and Oncology, Cancer, Cancer and Blood Disorders and Benign Blood Disorders, Cancer, Hematology Oncology and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Medical Oncology and Hematology, Cancer, Blood Diseases and Medical Oncology and Hematology, Cancer, Cancer and Blood Disorders and Bladder Cancer, Cancer, Hematology Oncology and Blood Cancers, Hospice and Palliative Care, Internal Medicine and Psychiatry, Hospice and Palliative Care and Palliative Care, Hospice and Palliative Care, Internal Medicine and Geriatrics, Sarah Lowry, D.N.P., ACNP-BC, AOCNP, ACHPN, Thomas G. DeLoughery, M.D., M.A.C.P., FAWM. (OHSU/Joe Rojas-Burke). By using this website, we will assume that you agree to the terms and conditions of our privacy policy. Very few institutions do it well, but OHSU truly gets it, Kummar says. PHYSICIAN HELPLINE Phone: 1-866-742-4811 Fax: 650-320-9443 Monday - Friday, 8 a.m. - 5 p.m. Stanford Health Care provides comprehensive services to refer and track patients, as well as the latest information and news for physicians and office staff. . Share on email. scripps institution of oceanography graduate programs; rosemont seneca advisors website Shivaani Kummar, MBBS is an Oncologist. Most recently, he was the director for Stanford SRI Drug Discovery and Development Program, and he trained with Nobel laureate Herb Brown at Purdue University. Give Now. The new early-phase research unit completes this expansion in the building. Shivaani Kummar is a Hematology & Medical Oncology Head at Oregon Health & Science University based in Portland, Oregon. 2001-2022 Oregon Health & Science University. My patients. OHSU researchers lead innovation and passion through new discoveries, comradery of the OHSU research community and the drive to improve peoples health and well-being. Dr. Shivaani Kummar is an oncologist in Palo Alto, California and is affiliated with OHSU Hospital. In addition to her role as division head, Kummar will serve as co-director for a new center in the Knight Cancer Institute, theCenter for Experimental Therapeutics, which she will co-lead with Sanjay Malhotra, Ph.D. Kummar brings a wealth of experience in conducting clinical trials tailored to make early, informed decisions regarding the suitability of new drug candidates for further clinical investigation. (OHSU/Joe Rojas-Burke), Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics, talks with OHSU Knight Cancer Institute Director Brian Druker, M.D., at the opening of OHSU's early-phase clinical trial unit in the Center for Health and Healing Building 2 on OHSU's South Waterfront campus, Aug. 23, 2021. bard college music faculty. L Fong, A Hotson, JD Powderly, M Sznol, RS Heist, TK Choueiri, S Kummar, A Chen, RE Parchment, RJ Kinders, J Ji, JE Tomaszewski, AF Farago, MS Taylor, RC Doebele, VW Zhu, S Kummar, AI Spira, S Kummar, M Gutierrez, ER Gardner, E Donovan, K Hwang, EJ Chung, Clinical Cancer Research 13 (18), 5411-5417. The Knight Cancer Institute's Center for Experimental Therapeutics (CET) represents multidisciplinary collaborations among scientists, physicians and engineers across OHSU. These new agents include those targeting genetic changes (alterations in the DNA of the cancer cell), those that harness the immune system to work against the cancer, and others. Privacy Notice: We use technologies, such as cookies, to customize content and advertising, to analyze traffic to the site and to provide a better overall experience to our users. Faculty and staff recruitment information. She runs early phase clinical trials evaluating new treatments while ensuring highest standards of patient safety. The OHSU Knight Cancer Institute has expanded its cancer research and care facilities to include a unit dedicated to serving patients participating in early-phase clinical trials. The provider's speciality is Internal Medicine with a focus in Medical Oncology How many years of experience does Dr. Shivaani Kummar have? Shivaani Kummar Dr. Kummar was recently appointed as Division Chief of Hematology and Oncology, and co-Director of the Center for Experimental Therapeutics, at the Oregon Health and Science University in Portland, Oregon. 2022 ASCO Annual Meeting - Poster Session . A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. If you proceed in scheduling an appointment and your healthinsurancebenefits do not participate with OHSU providers, your out of pocket liability may be higher. Visit thebilling andinsurancesection of our sitefor more information. The institute is involved with more than 400 clinical trials, including 113 early-phase trials. Shivaani Kummar, MD, FACP, is head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine, associate director for Clinical and Translational Research at the OHSU Knight Cancer Institute, and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics. We also share information about your use of our site with our trusted social media, advertising and analytics partners. SHIVAANI KUMMAR, 207RX0202X - Medical Oncology Doctors & Physicians in PORTLAND, OR. The new unit centralizes care for patients in research studies and expands capacity to allow more people to participate in early-phase clinical trials at OHSU. Username or E-mail. A Rajan, CA Carter, RJ Kelly, M Gutierrez, S Kummar, E Szabo, Clinical cancer research 18 (8), 2344-2351. She shares our urgency to better understand how research and drug development can help the patients who desperately need better treatments, today.. (44 Ratings, Learn more about clinical trials at the Knight Cancer Institute, The 13,000-square-foot early-phase research unit includes 12 treatment spaces, eight chairs, four beds, and procedure and consultation rooms. Equipment. middlesex county community college nursing program nj OHSU is an equal opportunity affirmative action institution. Home; NPI Lookup; Doctors; Medical Groups & Orgs; Taxonomy Codes; Lookup NPI Numbers from the NPI Registry . DS Hong, SG DuBois, S Kummar, AF Farago, CM Albert, KS Rohrberg, S Kummar, R Kinders, ME Gutierrez, L Rubinstein, RE Parchment, Journal of clinical oncology 27 (16), 2705. 1 - 20 out of 67 Results for "Shivaani Kummar" 67 Results Select All . OHSU is an equal opportunity affirmative action institution. edu h-index 8546 Citations 49 h-index 1996 2023 Research activity per year Overview Fingerprint Network Grants (5) Publications (174) Similar Profiles (1) If you made any changes in Pure these will be visible here soon. S Kummar, R Kinders, L Rubinstein, RE Parchment, AJ Murgo, J Collins, Journal of Soil and Water Conservation 53 (3), 230-240. A husband-wife team known for specializing in cancer drug development have joined the OHSU Knight Cancer Institute. Dr. Shivaani Kummar has primarily specialised in Medical Oncology for over 31 years. Under his leadership, the Knight Cancer Institute is actively engaged in doing so., Brian Druker, M.D., Knight Cancer Institute director, JELD-WEN Chair of Leukemia Research; investigator, Howard Hughes Medical Institute. Get to know some of the resear. Password. In her most recent role at Stanford University, Kummar held a number of titles, including: professor of medicine and radiology; associate division chief for academic affairs; director, phase I clinical research program; and co-director of the Translational Oncology Program. Verified email at ohsu.edu. Web Browser Accessibility, Oncology experts will head the Division of Hematology and Medical Oncology, direct new center for experimental therapeutics, Shivaani Kummar, M.D., and her husband Sanjay Malhotra, Ph.D., will co-lead the Knight Cancer institutes new Center for Experimental Therapeutics, uniting cutting-edge technologies with multidisciplinary preclinical and clinical investigators. Dr. Web Browser Accessibility, An open-label, multicenter Phase I dose escalation study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics and maximum tolerated dose of VIP152 (BAY 1251152) as monotherapy or combination therapy in subjects with advanced cancer. Patients and Methods. Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials. (h.c.), Ph.D., FAACR. The 13,000-square-foot early-phase research unit is located on the 12th floor of OHSUs Center for Health and Healing Building 2 on OHSUs South Waterfront campus. Shivaani Kummar, M.D., FACP Expertise Cancer Special focus Medical Oncology and Hematology Email this page Print this page About me Dr. Kummar is a cancer specialist whose focus is to bring new discoveries to the clinic, developing new treatments for cancer. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. OHSU HOSPITAL AND CLINICS: 380009: Provider Business Practice Location Address Details: Address: 3181 Sw Sam Jackson Park Rd, City: Portland . OHSU is an equal opportunity affirmative action institution. OHSU Knight Cancer Institute leaders include some of the most distinguished doctors and scientists in the world. Of that, $160 million was used for the Knight Cancer Research Building, which opened in 2018, and $40 million was used to build expanded capacity for clinical trial care in CHH2, which opened in 2019. shivaani kummar ohsu email. NPI Lookup NPI Database. The patient ratings score is an average of all responses to the question "How likely would you be to recommend this provider to your family and friends (on a scale of 0 to 10)" on our nationally-recognized NRC patient surveys. Select a country/territory to view shared publications and projects. A Drilon, TW Laetsch, S Kummar, SG DuBois, UN Lassen, GD Demetri, New England Journal of Medicine 378 (8), 731-739. Articles Cited by Public access. Year; Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children. . Notice of Privacy Practices We have a billion reasons why you should join us. Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's You can also correspond with Dr. Shivaani Kummar through mail at her mailing address at 3181 Sw Sam Jackson Park Rd, , Portland, Oregon - 97239-3011 (mailing address contact number . We are thrilled he is able to co-lead this new venture. 23() 'Oregon Health & Science University Knight Cancer Institute(OHSU)' BAL0891 1 Shivaani Kummar (Principal Investigator, PI), OHSU 'Mary Crowley Cancer Research . What sort of projects are you working on right now? Bergan, R., Coussens, L., McWeeney, S., Spellman, P., Streeter, P., Winters-Stone, K., Bagby, G., Mori, M., Corless, C., Harrington, C., Hoatlin, M., Koop, D., Magun, B., Druker, B., Shannon, J. Then we try to find what we call targets within or around cancer cells and develop drugs that can precisely hit those targets. In 2020, 470 Oregon residents from 28 counties consented to participate in clinical trial activities with the Knight Cancer Institute. Members receive periodic email communication about events, programming, news and funding opportunities. Early-phase trials are the first step in testing promising new medications and methods, and can offer patients early access to new and possibly better treatments. February 17, 2023 In Brief Edith Mitchell named enterprise vice president for cancer disparities at Jefferson SKCC A Ribas, T Medina, S Kummar, A Amin, A Kalbasi, JJ Drabick, M Barve, S Kummar, D Allen, A Monks, EC Polley, CD Hose, SP Ivy, IB Turkbey, Journal of Clinical Oncology 31 (18), 2296, Critical reviews in oncology/hematology 53 (3), 199-207, S Kummar, M Gutierrez, JH Doroshow, AJ Murgo, British journal of clinical pharmacology 62 (1), 15-26. Study Purpose. 2001-2022 Oregon Health & Science University. Our ability to collaborate with academics and industries across the globe will be paramount to our success in developing new drugs for patients. It is a privilege to be able to work in this field. Due to Covid-19 pandemic, the 2020 Symposium was postponed to 2021. General Information Email: ohsufinfo@ohsu.edu, Mailing Address Professor of Medicine, OHSU. Web Browser Accessibility, A PHASE 1/2 DOSE ESCALATION AND DOSE EXPANSION STUDY OF MECBOTAMAB VEDOTIN (BA3011) ALONE AND IN COMBINATION WITH NIVOLUMAB IN ADULT AND ADOLESCENT PATIENTS 12 YEARS AND OLDER WITH ADVANCED SOLID TUMORS, A Multicenter Phase 1/2, Open-Label Study of DCC-3014 to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics in Patients with Advanced Tumors and Tenosynovial Giant Cell Tumor, A Phase 1a/b Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination with Anticancer Therapies in Subjects with Solid Malignancies, A double-blind, placebo-controlled, randomized, dose-escalating, multicenter, Phase 1 study to assess the safety and tolerability of ART-123 in combination with leucovorin/5-fluorouracil/oxaliplatin and bevacizumab in metastatic colorectal cancer patients, A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion Study of Intravenously Administered 23ME-00610 in Patients with Advanced Solid Malignancies, A PHASE 1 STUDY OF KSQ-4279 ALONE AND IN COMBINATION IN PATIENTS WITH ADVANCED SOLID TUMORS. Stock and Other Ownership Interests: PathomIQ, Arxeon Therapeutics (I) Consulting or Advisory Role: Seattle Genetics, Bayer, Boehringer Ingelheim, Mundipharma EDO GmbH, Harbour BioMed, SpringWorks Therapeutics, Gilead Sciences, Mirati Therapeutics, EcoR1 Capital, Cadila Pharmaceuticals (I), Oxford BioTherapeutics. billing andinsurancesection of our site, Medical Oncology and Hematology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, American Board of Internal Medicine Board Certified in Internal Medicine, 1995-2005, Board Recertified in Internal Medicine, 2005-2015, Board Certified in Medical Oncology, 1998-2008, Board Recertified in Medical Oncology, 2008-2018; 2018-2028 Board Certified in Hematology, 2002-2012, Member, American Society of Clinical Oncology, Member, American Association for Cancer Research. 23 () 'Oregon Health & Science University Knight Cancer Institute (OHSU)' BAL0891 1 . By continuing you agree to the use of cookies. Recent progress in understanding the molecular basis of cellular processes, identification of promising therapeutic targets and evolution of the regulatory landscape makes this an exciting and unprecedented time to be in the field of oncology drug development. OHSU Foundation P.O. & Kummar, S. Research output: Contribution to journal Comment/debate peer-review, Research output: Contribution to journal Review article peer-review, Research output: Contribution to journal Article peer-review, Powered by Pure, Scopus & Elsevier Fingerprint Engine 2023 Elsevier B.V, We use cookies to help provide and enhance our service and tailor content. They have a high school-aged daughter and middle school-aged son. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. My clinical work is focused on conducting early phase clinical trials, enrolling and caring for patients on these trials. Shivaani Kummar (OHSU) kummar@ohsu.edu Upon completing her medical degree from Lady Hardinge Medical College in New Delhi, India, Shivaani Kummar moved to the United States to train in Internal Medicine at Emory University in Atlanta, Georgia. what was bolivar's ultimate goal? Vol.49 No.07. Philanthropy will allow us to expand the number of ongoing projects, including those focusing on rare tumors, as well as take on more pre- and post-doctoral students to train the next generation of cancer researchers. Sign up to receive the latest news, updates and stories from the OHSU Foundation in your inbox. Shivaani Kummar (Principal Investigator, PI). OHSU 'Mary Crowley Cancer . Response to treatment was evaluated at cycle 1 and every six cycles, that is, 18 weeks, by RECIST (Response Evaluation Criteria in Solid Tumors) version 1.1. We have a number of clinical trials investigating promising new strategies to treat cancer. Her research interests focus on developing novel therapies for cancer. Our patients in research studies can come in for their initial blood work and continue through their post treatment observation all in one place and are surrounded by a team of experts guiding them through the process.. Sort. Web Browser Accessibility, New early-phase clinical trial unit in the Center for Health and Healing Building 2 on South Waterfront centralizes care for cancer patients, provides more research opportunities, OHSU expands capacity for cancer clinical trials, OHSU Knight Cancer Institute: Understanding Cancer Clinical Trials, Expanding access to experimental cancer treatments in Oregon: Q&A with Shivaani Kummar, Severe respiratory illness season means boom times for OHSU virtual immediate care, OHSU leading effort to make cancer trials more inclusive, OHSU Child Life Specialist provides life-changing care to young patient living with chronic spinal condition, Making Hepatitis C care easier when treatment seems impossible. Across OHSU, doctors and researchers are reimagining early disease detection. Together they form a unique fingerprint. Malhotras impressive background in drug development will be key to cultivating this new center, says Druker, also the JELD-WEN Chair of Leukemia Research at OHSU. Shivaani Kummar, M.D., FACP, is head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institute's Center for Experimental Therapeutics. Shivaani Kummar, M.D., will lead the Division of Hematology and Medical Oncology in the OHSU School of Medicine, overseeing more than 90 faculty members. We are asking this question from time to time, and we expect to uncover a globe-full of roads to Stanford. Seventeen patients with desmoid tumors received PF-03084014 150 mg orally twice a day in 3-week cycles. To find better ways to treat patients. Clinical trials are research studies that test how well new medicines or treatments work in people. . OHSU is an equal opportunity affirmative action institution. All these new agents have shown promising anticancer activity in laboratory testing and are now being evaluated in patients. We are proud to be able to offer our patients access to the most advanced cancer therapies available, said Shivaani Kummar, M.D., FACP, head of the Division of Hematology and Medical Oncology in the OHSU School of Medicine and co-director of the Knight Cancer Institutes Center for Experimental Therapeutics. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Dr. Cited by. The Division of Hematology and Medical Oncology is headed byShivaani Kummar, M.D., FACPand composed of many sections: Kathleen Beebe Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. February 17, 2023. Together they have built a strong record of discovery, innovation and care. Shivaani Kummar Stanford University Medical Center - PMWC Precision Medicine World Conference Speaker Profile M.D., Professor of Medicine and Radiology, Stanford University; Director, Phase I Clinical Research Program-Medical Oncology; Director, Translational Oncology Program At Stanford Shivaani Kummar Biography Recent external collaboration on country/territory level. S Kummar, J Ji, R Morgan, HJ Lenz, SL Puhalla, CP Belani, DR Gandara, Clinical Cancer Research 18 (6), 1726-1734. This trial will study tisotumab vedotin to find out whether it is an effective treatment for certain solid tumors and what side effects (unwanted effects) may occur. Read more to learn about Shivaani Kummar, MBBS's background, education, and other specialties. Within our Center for Experimental Therapeutics, Knight Cancer Institute, we have multiple ongoing projects trying to identify new ways to target cancer. Oregon Health & Science University is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. OHSU is dedicated to improving the health and quality of life for all Oregonians through excellence, innovation and leadership in health care, education and research. Office 3181 SW Sam Jackson Park Rd Portland, OR 97239 Phone+1 503-280-1223 Is this information wrong? The purpose of the study is to learn more about the study drug, VIP152, in combination with pembrolizumab in people with advanced or . OHSU HOSPITAL AND CLINICS - (Acute Care) 3181 SW SAM JACKSON PARK ROAD She received her medical degree from Lady Hardinge Medical College and has been in practice for . Administrative Coordinator, Felicia Feingersch OHSU is an equal opportunity affirmative action institution. The couple says their ultimate goal is to develop new effective therapies for cancer. Sanjay Malhotra, Ph.D. Shivaani Kummar, M.D., FACP When were developing new treatments for cancer, we are often trying to identify what makes the cancer different from normal cells or why currently used drugs are not working as well as we would like them to. The Center for Experimental Therapeutics is co-led by Sanjay Malhotra, Ph.D., and Shivaani Kummar, M.D. 11 Jun 2022. Why are early phase clinical trials important for advancing the care of people with cancer? In Brief. She currently practices at Oregon Health And Sciencs University Primary Care Clinic and is affiliated with Stanford Health Care. Dr. Kummar specializes in the care and treatment of patients with cancer. The center is designed to advance innovation efforts within the Knight Cancer Institute to discover and develop new treatments for cancer, from early phase clinical trials, to drug development.
Dailey And Vincent Band Members 2020,
Optus Stadium Food 2022,
Umaine Football Roster,
Articles S
